<DOC>
	<DOC>NCT01684969</DOC>
	<brief_summary>This will be a blinded study to compare the absorption of topical haloperidol with placebo</brief_summary>
	<brief_title>Evidence of Haloperidol Absorption After Topical Administration</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Inclusion Criteria Age: patient must be 18 years or older and less than 70 years of age. Provision of informed consent No previous adverse reaction to haloperidol No current use of haloperidol Good health No alcohol within 24 hours of the study No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease. Normal neurologic exam Exclusionary Criteria Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study Recent cerebral trauma Study will exclude women who are pregnant and/or nursing Women who are of child bearing potential must have a negative urine pregnancy test. History of seizures Taking medications that can interact with haloperidol Subjects with significant cardiovascular (cardiac conduction deficits), gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Nausea</keyword>
	<keyword>vomiting</keyword>
	<keyword>gastrointestinal symptoms</keyword>
	<keyword>palliative care</keyword>
</DOC>